Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 75
Filter
1.
Tuberculosis (Edinb) ; 143: 102409, 2023 12.
Article in English | MEDLINE | ID: mdl-37729851

ABSTRACT

Type I interferon (IFN)-induced genes have the potential for distinguishing active tuberculosis (ATB) from latent TB infection (LTBI) and healthy controls (HC), monitoring treatment, and detection of individuals at risk of progression to active disease. We examined the differential effects of IFN-α, IFN-ß and Mycobacterium tuberculosis whole cell lysate (Mtb WCL) stimulation on the expression of selected IFN-stimulated genes in peripheral blood mononuclear cells from individuals with either LTBI, ATB, and healthy controls. Stimulation with IFN-α and IFN-ß induced a higher expression of the interrogated genes while Mtb WCL stimulation induced expression similar to that observed at baseline, with the exception of IL-1A and IL-1B genes that were downregulated. The expression of IFN-α-induced FCGR1A gene, IFN-ß-induced FCGR1A, FCGR1B, and SOCS3 genes, and Mtb WCL-induced IFI44, IFI44L, IFIT1, and IFITM3 genes differed significantly between LTBI and ATB. These findings suggest stimulation-driven gene expression patterns could potentially discriminate LTBI and ATB. Mechanistic studies are necessary to define the processes through which distinct type I IFNs and downstream ISGs determine infection outcomes and identify potential host-directed therapeutic strategies.


Subject(s)
Interferon Type I , Latent Tuberculosis , Mycobacterium tuberculosis , Tuberculosis , Humans , Mycobacterium tuberculosis/genetics , Latent Tuberculosis/diagnosis , Latent Tuberculosis/genetics , Interferon Type I/genetics , Leukocytes, Mononuclear , Antigens, Bacterial/genetics , Tuberculosis/diagnosis , Tuberculosis/genetics , Membrane Proteins , RNA-Binding Proteins
2.
Nat Commun ; 13(1): 3357, 2022 06 10.
Article in English | MEDLINE | ID: mdl-35688805

ABSTRACT

Vaccines against SARS-CoV-2 have shown high efficacy in clinical trials, yet a full immunologic characterization of these vaccines, particularly within the human upper respiratory tract, is less well known. Here, we enumerate and phenotype T cells in nasal mucosa and blood using flow cytometry before and after vaccination with the Pfizer-BioNTech COVID-19 vaccine (n = 21). Tissue-resident memory (Trm) CD8+ T cells expressing CD69+CD103+ increase in number ~12 days following the first and second doses, by 0.31 and 0.43 log10 cells per swab respectively (p = 0.058 and p = 0.009 in adjusted linear mixed models). CD69+CD103+CD8+ T cells in the blood decrease post-vaccination. Similar increases in nasal CD8+CD69+CD103- T cells are observed, particularly following the second dose. CD4+ cells co-expressing CCR6 and CD161 are also increased in abundance following both doses. Stimulation of nasal CD8+ T cells with SARS-CoV-2 spike peptides elevates expression of CD107a at 2- and 6-months (p = 0.0096) post second vaccine dose, with a subset of donors also expressing increased cytokines. These data suggest that nasal T cells may be induced and contribute to the protective immunity afforded by this vaccine.


Subject(s)
CD8-Positive T-Lymphocytes , COVID-19 , BNT162 Vaccine , CD4-Positive T-Lymphocytes , COVID-19/prevention & control , COVID-19 Vaccines , Humans , Immunologic Memory , NK Cell Lectin-Like Receptor Subfamily B/immunology , Nasal Mucosa , RNA, Messenger , Receptors, CCR6 , SARS-CoV-2 , Vaccination
3.
AIDS ; 35(7): 1091-1101, 2021 06 01.
Article in English | MEDLINE | ID: mdl-33534201

ABSTRACT

OBJECTIVE: Both HIV infection and identifying as MSM have been linked to altered rectal microbiota composition, but few studies have studied sexual behavioural associations with rectal microbiota within MSM. In addition, most rectal microbiota studies in MSM have been limited geographically to Europe and North America, and replication of findings in lower and middle-income countries is lacking. DESIGN: A cross-sectional study. METHODS: We enrolled MSM from Nairobi, Kenya, and determined their HIV/sexually transmitted infection status. Rectal specimens were obtained for 16s rRNA sequencing of the rectal microbiota, and sexual behaviour was characterized using a standardized questionnaire. Microbiome differences were modelled using nonparametric statistics, Bray-Curtis ecological distance metrics and analyses of differential taxa abundance. Multivariable linear regression was used to model HIV status and recent sexual activity as predictors of alpha diversity, controlling for a range of covariates. RESULTS: Alpha diversity was consistently lower in Kenyan HIV-infected MSM (n = 80), including those on antiretroviral therapy (ART) compared with HIV-uninfected MSM. A statistical trend was observed for clustering of HIV status by Prevotella or Bacteroides dominance (P = 0.13). Several taxa were enriched in HIV-positive men, including Roseburia, Lachnospira, Streptococcus and Granulicatella. Receptive anal sex with several types of sexual partners (paying, regular, casual) was associated with lower Chao1 and Simpson diversity, independent of HIV status, while HIV infection was associated lower Chao1 (P = 0.030) but not Simpson diversity (P = 0.49). CONCLUSION: Both HIV infection and sexual behaviour were associated with rectal microflora alpha diversity, in particular richness, but not Prevotella spp. dominance, in Kenyan MSM. Associations were more robust for sexual behaviour.


Subject(s)
HIV Infections , Microbiota , Sexual and Gender Minorities , Cross-Sectional Studies , Europe , HIV Infections/complications , Homosexuality, Male , Humans , Kenya , Male , North America , Prevalence , RNA, Ribosomal, 16S/genetics , Sexual Behavior
4.
BMC Med Genomics ; 13(1): 28, 2020 02 17.
Article in English | MEDLINE | ID: mdl-32066441

ABSTRACT

BACKGROUND: Influenza infections produce a spectrum of disease severity, ranging from a mild respiratory illness to respiratory failure and death. The host-response pathways associated with the progression to severe influenza disease are not well understood. METHODS: To gain insight into the disease mechanisms associated with progression to severe infection, we analyzed the leukocyte transcriptome in severe and moderate influenza patients and healthy control subjects. Pathway analysis on differentially expressed genes was performed using a topology-based pathway analysis tool that takes into account the interaction between multiple cellular pathways. The pathway profiles between moderate and severe influenza were then compared to delineate the biological mechanisms underpinning the progression from moderate to severe influenza. RESULTS: 107 patients (44 severe and 63 moderate influenza patients) and 52 healthy control subjects were included in the study. Severe influenza was associated with upregulation in several neutrophil-related pathways, including pathways involved in neutrophil differentiation, migration, degranulation and neutrophil extracellular trap (NET) formation. The degree of upregulation in neutrophil-related pathways were significantly higher in severely infected patients compared to moderately infected patients. Severe influenza was also associated with downregulation in immune response pathways, including pathways involved in antigen presentation such as CD4+ T-cell co-stimulation, CD8+ T cell and Natural Killer (NK) cells effector functions. Apoptosis pathways were also downregulated in severe influenza patients compare to moderate and healthy controls. CONCLUSIONS: These findings showed that there are changes in gene expression profile that may highlight distinct pathogenic mechanisms associated with progression from moderate to severe influenza infection.


Subject(s)
Gene Expression Regulation , Influenza, Human/metabolism , Leukocytes/metabolism , Transcriptome , Adult , Aged , Female , Humans , Influenza, Human/genetics , Influenza, Human/pathology , Leukocytes/pathology , Male , Middle Aged , Severity of Illness Index
5.
PLoS One ; 14(9): e0222878, 2019.
Article in English | MEDLINE | ID: mdl-31550271

ABSTRACT

INTRODUCTION: Mucosal immune activation, in the context of sexual transmission of HIV-1 infection, is crucial, as the increased presence of activated T cells enhance susceptibility to infection. In this regard, it has been proposed that immunomodulatory compounds capable of modulating immune activation, such as Vitamin D (VitD) may reduce HIV-1 transmission and might be used as a safe and cost-effective strategy for prevention. Considering this, we examined the in vitro effect of the treatment of peripheral blood mononuclear cells (PBMCs) with the active form of VitD, calcitriol, on cellular activation, function and susceptibility of CD4+ T cells to HIV-1 infection. METHODS: We treated PBMCs from healthy HIV unexposed individuals (Co-HC) and frequently exposed, HIV-1 seronegative individuals (HESNs) from Colombia and from healthy non-exposed individuals from Canada (Ca-HC) with calcitriol and performed in vitro HIV-1 infection assays using X4- and R5-tropic HIV-1 strains respectively. In addition, we evaluated the activation and function of T cells and the expression of viral co-receptors, and select antiviral genes following calcitriol treatment. RESULTS: Calcitriol reduced the frequency of infected CD4+ T cells and the number of viral particles per cell, for both, X4- and R5-tropic viruses tested in the Co-HC and the Ca-HC, respectively, but not in HESNs. Furthermore, in the Co-HC, calcitriol reduced the frequency of polyclonally activated T cells expressing the activation markers HLA-DR and CD38, and those HLA-DR+CD38-, whereas increased the subpopulation HLA-DR-CD38+. Calcitriol treatment also decreased production of granzyme, IL-2 and MIP-1ß by T cells and increased the transcriptional expression of the inhibitor of NF-kB and the antiviral genes cathelicidin (CAMP) and APOBEC3G in PBMCs from Co-HC. CONCLUSION: Our in vitro findings suggest that VitD treatment could reduce HIV-1 transmission through a specific modulation of the activation levels and function of T cells, and the production of antiviral factors. In conclusion, VitD remains as an interesting potential strategy to prevent HIV-1 transmission that should be further explored.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Calcitriol/administration & dosage , HIV Infections/prevention & control , Lymphocyte Activation/drug effects , Vitamins/administration & dosage , APOBEC-3G Deaminase/immunology , APOBEC-3G Deaminase/metabolism , Antimicrobial Cationic Peptides/immunology , Antimicrobial Cationic Peptides/metabolism , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/metabolism , Cells, Cultured , Female , HIV Infections/blood , HIV Infections/transmission , HIV Infections/virology , HIV-1/immunology , HIV-1/pathogenicity , HLA-DR Antigens/immunology , HLA-DR Antigens/metabolism , Humans , Immunity, Mucosal/drug effects , Male , Primary Cell Culture , Cathelicidins
6.
Nat Commun ; 10(1): 3422, 2019 07 31.
Article in English | MEDLINE | ID: mdl-31366921

ABSTRACT

Severe influenza infection has no effective treatment available. One of the key barriers to developing host-directed therapy is a lack of reliable prognostic factors needed to guide such therapy. Here, we use a network analysis approach to identify host factors associated with severe influenza and fatal outcome. In influenza patients with moderate-to-severe diseases, we uncover a complex landscape of immunological pathways, with the main changes occurring in pathways related to circulating neutrophils. Patients with severe disease display excessive neutrophil extracellular traps formation, neutrophil-inflammation and delayed apoptosis, all of which have been associated with fatal outcome in animal models. Excessive neutrophil activation correlates with worsening oxygenation impairment and predicted fatal outcome (AUROC 0.817-0.898). These findings provide new evidence that neutrophil-dominated host response is associated with poor outcomes. Measuring neutrophil-related changes may improve risk stratification and patient selection, a critical first step in developing host-directed immune therapy.


Subject(s)
Extracellular Traps/immunology , Influenza, Human/immunology , Influenza, Human/pathology , Neutrophil Activation/immunology , Neutrophils/immunology , Cell Cycle/immunology , Female , Gene Expression/genetics , Humans , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza A Virus, H3N2 Subtype/immunology , Influenza A Virus, H3N2 Subtype/isolation & purification , Influenza B virus/immunology , Influenza B virus/isolation & purification , Influenza, Human/mortality , Lung/immunology , Male , Middle Aged , Prospective Studies , Respiration, Artificial , Respiratory Insufficiency/mortality , Respiratory Insufficiency/pathology , Respiratory Insufficiency/virology
7.
Front Immunol ; 9: 1076, 2018.
Article in English | MEDLINE | ID: mdl-29868028

ABSTRACT

Background: End-stage renal disease (ESRD) is associated with an increased susceptibility to infectious diseases, including infection with Mycobacterium tuberculosis (Mtb). Mucosal-associated invariant T (MAIT) cells recognize vitamin B metabolites produced by many bacterial species, including Mtb, and may play an important role in providing protective immunity against tuberculosis infection in the lung. To date, little is known about MAIT cell frequency, phenotype, or function in ESRD patients. Methods: MAIT cells, identified by surface marker expression or MR1 tetramer binding, were characterized in 20 ESRD and 20 healthy control participants by multicolor flow cytometry. Ex vivo MAIT cell phenotype and cytokine production following PMA/ionomycin, IL-12/IL-18, or Escherichia coli stimulation were determined. Monocyte phenotype and plasma C-reactive protein/inflammatory cytokine levels were quantified by flow cytometry, ELISA, and multiplex bead array. Results: Peripheral blood MAIT cells were significantly depleted among ESRD patients compared to controls by both phenotypic and tetramer analysis and exhibited a loss of CXCR3 expression coupled to increased expression of CCR6 and CXCR6. ESRD was also associated with a shift in MAIT PMA-induced cytokine production away from IFNγ production and toward granulocyte macrophage-colony stimulating factor (GM-CSF) secretion, and a loss of E. coli-stimulated tumor necrosis factor α expression. Loss of IFNγ expression was associated with a combination of age, alterations in Tbet and Eomes expression, and inflammatory plasma cytokine levels. Conclusion: The loss of peripheral blood MAIT cells and associated shifts in tissue homing receptor expression and GM-CSF production may contribute to an immune environment that is permissive to bacterial replication, particularly in the lungs.


Subject(s)
Gene Expression Regulation , Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/metabolism , Mucosal-Associated Invariant T Cells/immunology , Mucosal-Associated Invariant T Cells/metabolism , Receptors, Chemokine/genetics , Adult , Aged , Biomarkers , Cells, Cultured , Cytokines/metabolism , Cytokines/pharmacology , Female , Humans , Immunophenotyping , Interferon-gamma Release Tests , Kidney Failure, Chronic/pathology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Lymphocyte Activation/immunology , Lymphocyte Depletion , Male , Middle Aged , Mucosal-Associated Invariant T Cells/drug effects , Phenotype , Receptors, Chemokine/metabolism
8.
Kidney Int ; 92(4): 1003-1014, 2017 10.
Article in English | MEDLINE | ID: mdl-28651949

ABSTRACT

Patients with end-stage renal disease (ESRD) are at elevated risk of acquiring infectious diseases, including tuberculosis (TB). Inflammation and uremia negatively impact immune function in this population, but specific pathways involved in TB immunity have not been identified. Although γδ T cells are known to contribute to protection from TB, their phenotype and function in patients with ESRD is relatively unknown. To determine this we recruited 20 patients with and 20 without ESRD (controls), with or without latent TB infection to assess γδ T cell frequency, surface phenotype, and cytokine production by flow cytometry in response to stimulation. γδ T cells derived from patients with ESRD exhibited significantly lower expression of CCR5, CXCR3, and CD26 compared to controls. Furthermore, patients with ESRD, particularly the group with latent TB infection, exhibited poor IFNγ, TNFα, and GMCSF responses to stimulation with either phosphoantigen HMB-PP, IL-12/IL-18, E. coli, or phorbol myristate acetate and ionomycin. Similar dysfunctional responses were observed in patients with active TB. Surprisingly, neither the γδ phenotype nor its function was associated with plasma markers of inflammation or microbial translocation. Thus, there is significant perturbation of the γδ T-cell population in patients with ESRD, particularly in those with latent TB infection.


Subject(s)
Cytokines/metabolism , Intraepithelial Lymphocytes/immunology , Kidney Failure, Chronic/immunology , Latent Tuberculosis/immunology , Mycobacterium tuberculosis/pathogenicity , Adult , Aged , Cytokines/immunology , Diphosphates , Disease Susceptibility/immunology , Disease Susceptibility/microbiology , Female , Flow Cytometry , Humans , Intraepithelial Lymphocytes/metabolism , Kidney Failure, Chronic/urine , Latent Tuberculosis/microbiology , Lymphocyte Activation/immunology , Male , Middle Aged , Mycobacterium tuberculosis/isolation & purification , Uremia/immunology , Uremia/urine
9.
J Virol ; 91(13)2017 07 01.
Article in English | MEDLINE | ID: mdl-28424286

ABSTRACT

There are marked differences in the spread and prevalence of HIV-1 subtypes worldwide, and differences in clinical progression have been reported. However, the biological reasons underlying these differences are unknown. Gag-protease is essential for HIV-1 replication, and Gag-protease-driven replication capacity has previously been correlated with disease progression. We show that Gag-protease replication capacity correlates significantly with that of whole isolates (r = 0.51; P = 0.04), indicating that Gag-protease is a significant contributor to viral replication capacity. Furthermore, we investigated subtype-specific differences in Gag-protease-driven replication capacity using large well-characterized cohorts in Africa and the Americas. Patient-derived Gag-protease sequences were inserted into an HIV-1 NL4-3 backbone, and the replication capacities of the resulting recombinant viruses were measured in an HIV-1-inducible reporter T cell line by flow cytometry. Recombinant viruses expressing subtype C Gag-proteases exhibited substantially lower replication capacities than those expressing subtype B Gag-proteases (P < 0.0001); this observation remained consistent when representative Gag-protease sequences were engineered into an HIV-1 subtype C backbone. We identified Gag residues 483 and 484, located within the Alix-binding motif involved in virus budding, as major contributors to subtype-specific replicative differences. In East African cohorts, we observed a hierarchy of Gag-protease-driven replication capacities, i.e., subtypes A/C < D < intersubtype recombinants (P < 0.0029), which is consistent with reported intersubtype differences in disease progression. We thus hypothesize that the lower Gag-protease-driven replication capacity of subtypes A and C slows disease progression in individuals infected with these subtypes, which in turn leads to greater opportunity for transmission and thus increased prevalence of these subtypes.IMPORTANCE HIV-1 subtypes are unevenly distributed globally, and there are reported differences in their rates of disease progression and epidemic spread. The biological determinants underlying these differences have not been fully elucidated. Here, we show that HIV-1 Gag-protease-driven replication capacity correlates with the replication capacity of whole virus isolates. We further show that subtype B displays a significantly higher Gag-protease-mediated replication capacity than does subtype C, and we identify a major genetic determinant of these differences. Moreover, in two independent East African cohorts we demonstrate a reproducible hierarchy of Gag-protease-driven replicative capacity, whereby recombinants exhibit the greatest replication, followed by subtype D, followed by subtypes A and C. Our data identify Gag-protease as a major determinant of subtype differences in disease progression among HIV-1 subtypes; furthermore, we propose that the poorer viral replicative capacity of subtypes A and C may paradoxically contribute to their more efficient spread in sub-Saharan Africa.


Subject(s)
Disease Progression , Genotype , HIV Infections/pathology , HIV Infections/virology , HIV-1/physiology , Virus Replication , gag Gene Products, Human Immunodeficiency Virus/genetics , Africa, Eastern , Genetic Variation , HIV-1/classification , HIV-1/genetics , Humans , Virus Release
10.
Clin Immunol ; 168: 55-63, 2016 07.
Article in English | MEDLINE | ID: mdl-27181992

ABSTRACT

End-stage renal disease (ESRD) patients exhibit elevated risk of tuberculosis (TB) reactivation, but current diagnostics, including the interferon gamma release assay (IGRA), exhibit poor sensitivity in ESRD. We tested 80 ESRD patients and found an 18.75% prevalence of IGRA positivity. A subset of patients was assessed for Mtb-specific expression of 44 cytokines/chemokines, and CD4+ T cell phenotype and function. Similar to non-ESRD IGRA+ individuals, Mtb-specific IFNγ, IL-1RA, IP-10, MCP-3 and IL-2 responses were identified in the ESRD IGRA+ group. 27% of the ESRD IGRA- group exhibited MCP-3 or IL-2 Mtb-specific responses, which may identify cases of latent TB infection in ESRD. Stimulation of PBMC with PPD demonstrated similar CD4+ T cell production of IFNγ, TNFα and GM-CSF by ESRD patients. The reported low sensitivity of the IGRA in ESRD cohorts is therefore unlikely to be due to poor T cell cytokine secretion, and may instead reflect defects in antigen presentation.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Kidney Failure, Chronic/immunology , Latent Tuberculosis/immunology , Mycobacterium tuberculosis/immunology , Aged , CD4-Positive T-Lymphocytes/metabolism , Cells, Cultured , Chemokine CCL7/immunology , Chemokine CCL7/metabolism , Cytokines/immunology , Cytokines/metabolism , Female , Flow Cytometry , Host-Pathogen Interactions/immunology , Humans , Interferon-gamma/immunology , Interferon-gamma/metabolism , Kidney Failure, Chronic/metabolism , Latent Tuberculosis/diagnosis , Latent Tuberculosis/microbiology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , Mycobacterium tuberculosis/physiology , ROC Curve
12.
Tuberculosis (Edinb) ; 95(5): 555-61, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26073895

ABSTRACT

Mycobacterium tuberculosis (Mtb) infects nearly 2 million people annually and is the most common cause of death in HIV-infected individuals. Tuberculosis (TB) diagnostics cater to HIV-uninfected individuals in non-endemic countries, are expensive, slow, and lack sensitivity for those most affected. Patterns of soluble immune markers from Mtb-stimulated immune cells are not well defined in HIV co-infection. We assessed immune differences between HIV-infected and HIV-uninfected individuals with active TB utilizing IFNγ-based QuantiFERON®-TB Gold In-Tube (QFT) testing in Nairobi, Kenya. Excess QFT supernatants were used to measure cytokine and chemokine responses by a 17-plex bead array. Mtb/HIV co-infected participants were significantly less likely to be QFT+ (47.2% versus 84.2% in the HIV-uninfected group), and demonstrated lower expression of all cytokines except for IFNα2. Receiver operator characteristic analyses identified IL-1α as a potential marker of co-infection. Among HIV-infected individuals, CD4+ T cell count correlated weakly with the expression of several analytes. Co-expression analysis highlighted differences in immune profiles between the groups. These data suggest that there is a unique and detectable Mtb-specific immune response in co-infection. A better understanding of Mtb immunology can translate into much needed immunodiagnostics with enhanced sensitivity in HIV-infected individuals, facilitating their opportunity to obtain live-saving treatment.


Subject(s)
Chemokines/blood , Coinfection , Cytokines/blood , HIV Infections/blood , Mycobacterium tuberculosis/immunology , Tuberculosis, Pulmonary/blood , Adult , Area Under Curve , Biomarkers/blood , Female , HIV Infections/diagnosis , HIV Infections/immunology , HIV Infections/virology , Host-Pathogen Interactions , Humans , Interferon-gamma/blood , Interferon-gamma Release Tests , Kenya , Male , Middle Aged , Mycobacterium tuberculosis/pathogenicity , Predictive Value of Tests , ROC Curve , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/immunology , Tuberculosis, Pulmonary/microbiology
13.
Sci Rep ; 5: 11253, 2015 Jun 17.
Article in English | MEDLINE | ID: mdl-26082240

ABSTRACT

Cytotoxic T lymphocyte (CTL) responses against the HIV Gag protein are associated with lowering viremia; however, immune control is undermined by viral escape mutations. The rapid viral mutation rate is a key factor, but recombination may also contribute. We hypothesized that CTL responses drive the outgrowth of unique intra-patient HIV-recombinants (URFs) and examined gag sequences from a Kenyan sex worker cohort. We determined whether patients with HLA variants associated with effective CTL responses (beneficial HLA variants) were more likely to carry URFs and, if so, examined whether they progressed more rapidly than patients with beneficial HLA-variants who did not carry URFs. Women with beneficial HLA-variants (12/52) were more likely to carry URFs than those without beneficial HLA variants (3/61) (p < 0.0055; odds ratio = 5.7). Beneficial HLA variants were primarily found in slow/standard progressors in the URF group, whereas they predominated in long-term non-progressors/survivors in the remaining cohort (p = 0.0377). The URFs may sometimes spread and become circulating recombinant forms (CRFs) of HIV and local CRF fragments were over-represented in the URF sequences (p < 0.0001). Collectively, our results suggest that CTL-responses associated with beneficial HLA variants likely drive the outgrowth of URFs that might reduce the positive effect of these CTL responses on disease progression.


Subject(s)
Genetic Variation , HIV Infections/virology , HIV-1/genetics , Recombination, Genetic , Sex Workers , Adult , Disease Progression , Female , Genotype , HIV Core Protein p24/genetics , HLA Antigens/genetics , Humans , Leukocytes, Mononuclear/virology , Molecular Typing , Mutation , gag Gene Products, Human Immunodeficiency Virus/genetics
15.
Elife ; 42015 Feb 03.
Article in English | MEDLINE | ID: mdl-25647729

ABSTRACT

Tenofovir gel is being evaluated for vaginal and rectal pre-exposure prophylaxis against HIV transmission. Because this is a new prevention strategy, we broadly assessed its effects on the mucosa. In MTN-007, a phase-1, randomized, double-blinded rectal microbicide trial, we used systems genomics/proteomics to determine the effect of tenofovir 1% gel, nonoxynol-9 2% gel, placebo gel or no treatment on rectal biopsies (15 subjects/arm). We also treated primary vaginal epithelial cells from four healthy women with tenofovir in vitro. After seven days of administration, tenofovir 1% gel had broad-ranging effects on the rectal mucosa, which were more pronounced than, but different from, those of the detergent nonoxynol-9. Tenofovir suppressed anti-inflammatory mediators, increased T cell densities, caused mitochondrial dysfunction, altered regulatory pathways of cell differentiation and survival, and stimulated epithelial cell proliferation. The breadth of mucosal changes induced by tenofovir indicates that its safety over longer-term topical use should be carefully monitored.


Subject(s)
Mucous Membrane/drug effects , Reverse Transcriptase Inhibitors/administration & dosage , Tenofovir/administration & dosage , Double-Blind Method , Female , Gels , Gene Expression/drug effects , Humans , Male , Mitochondria/drug effects , Mucous Membrane/metabolism , Proteomics , Rectum/drug effects , Rectum/metabolism , Reverse Transcriptase Inhibitors/adverse effects , Tenofovir/adverse effects , Vagina/drug effects , Vagina/metabolism
16.
AIDS ; 29(1): 35-41, 2015 Jan 02.
Article in English | MEDLINE | ID: mdl-25562491

ABSTRACT

INTRODUCTION: Recent studies have identified Mx2 as a novel HIV-1 innate restriction factor that inhibits proviral integration. A pilot proteomic study of immune cells from highly exposed HIV-seronegative (HESN) individuals enrolled in the Pumwani sex worker cohort identified Mx1 as potential correlate of HIV protection. A detailed population level analysis of Mx1 and Mx2 expression and their role in reduced susceptibility to HIV infection in HESN women was conducted. METHODS: Peripheral blood mononuclear cells (PBMC) were isolated from 102 HESN women and 100 high-risk negative controls enrolled in a Nairobi-based sex worker cohort. Whole-cell lysates were prepared and analyzed for Mx1 and Mx2 expression by commercial ELISA. Bivariate and multiple linear regression analyses were conducted to account for confounding epidemiological factors. RESULTS: Mx2, but not Mx1, was found to be significantly overexpressed in HESN women compared with high-risk negative controls (P = 0.027). After multiple linear regression analysis, accounting for age, menopause, pregnancy, Depo-Provera use, recent infections and medication usage, Mx2 expression remained significantly overexpressed in the PBMC of HESN women (P = 0.05). Additionally, an interaction model analysis indicated that HESN women who use Depo-Provera have 2.6-fold higher levels of Mx2 than any other group (P < 0.001). No associations with Mx1 expression were observed. CONCLUSION: This is the first epidemiological report of Mx2 and its association with altered susceptibility to HIV infection in HESN women. Additionally, we show that HESN women who use Depo-Provera have the highest levels of Mx2 expression, highlighting a possible mechanism for hormonal modulation of HIV susceptibility.


Subject(s)
Disease Susceptibility/immunology , HIV Seronegativity/immunology , Leukocytes, Mononuclear/immunology , Myxovirus Resistance Proteins/immunology , Adult , Female , HIV Infections/epidemiology , HIV-1 , Humans , Immunity, Innate , Kenya/epidemiology , Medroxyprogesterone Acetate/therapeutic use , Proteomics , Sex Workers
17.
PLoS One ; 9(8): e103391, 2014.
Article in English | MEDLINE | ID: mdl-25105290

ABSTRACT

BACKGROUND: CD4 T cell enumeration is the most widely used prognostic marker for management of HIV disease. Internal quality control and external quality assessment (EQA) programs are critical to ensure reliability of clinical measurements. The utility of stabilized whole blood products (SWBP) as a test reagent for EQA programs such as Quality Assessment and Standardization for Immunological measures relevant to HIV/AIDS (QASI) program have been demonstrated previously. Since then, several new commercial SWBPs and alternative CD4 enumeration technologies have become available. Seven SWBPs were evaluated on seven different enumeration platforms to determine which product(s) are most suitable for EQA programs that support multiple analytical technologies. METHOD: Assessment of SWBPs was based on two criteria: (1) accuracy of CD4 T cell measurements and; (2) stability under sub optimal storage conditions. RESULTS: Three SWBPs (Multi-Check, StatusFlow and CD4 Count) showed accurate CD4 T-cell absolute count and percentage values across six of the enumeration platforms. All products retain stability up to 18 days at 21-23°C with the exception of Multi-Check-high on FacsCount and Multi-Check-Low and StatusFlow-Low on Pima. One of the products (CD4 Count) retained stability for three days on all platforms tested when stored at 37°C. CONCLUSION: This study demonstrated that the characteristics of commercially available SWBPs vary across multiple CD4 platforms. The compatibility of testing panels for EQA programs with multiple analytical platforms needs to be carefully considered, especially in large multiplatform CD4 EQA programs. The selection of a suitable cross-platform SWBP is an increasing challenge as more reagents and platforms are introduced for CD4 T-cell enumeration.


Subject(s)
Biological Products , Blood/immunology , CD4-Positive T-Lymphocytes/cytology , Cell Count/methods , HIV Seropositivity/blood , HIV Seropositivity/diagnosis , Biological Products/chemistry , Cell Count/standards , Humans , Immunophenotyping/methods , Quality Control
18.
PLoS One ; 9(6): e100820, 2014.
Article in English | MEDLINE | ID: mdl-24978053

ABSTRACT

OBJECTIVE: Sexual transmission of HIV occurs across a mucosal surface, which contains many soluble immune factors important for HIV immunity. Although the composition of mucosal fluids in the vaginal and oral compartments has been studied extensively, the knowledge of the expression of these factors in the rectal mucosa has been understudied and is very limited. This has particular relevance given that the highest rates of HIV acquisition occur via the rectal tract. To further our understanding of rectal mucosa, this study uses a proteomics approach to characterize immune factor components of rectal fluid, using saliva as a comparison, and evaluates its antiviral activity against HIV. METHODS: Paired salivary fluid (n = 10) and rectal lavage fluid (n = 10) samples were collected from healthy, HIV seronegative individuals. Samples were analyzed by label-free tandem mass spectrometry to comprehensively identify and quantify mucosal immune protein abundance differences between saliva and rectal fluids. The HIV inhibitory capacity of these fluids was further assessed using a TZM-bl reporter cell line. RESULTS: Of the 315 proteins identified in rectal lavage fluid, 72 had known immune functions, many of which have described anti-HIV activity, including cathelicidin, serpins, cystatins and antileukoproteinase. The majority of immune factors were similarly expressed between fluids, with only 21 differentially abundant (p<0.05, multiple comparison corrected). Notably, rectal mucosa had a high abundance of mucosal immunoglobulins and antiproteases relative to saliva, Rectal lavage limited HIV infection by 40-50% in vitro (p<0.05), which is lower than the potent anti-HIV effect of oral mucosal fluid (70-80% inhibition, p<0.005). CONCLUSIONS: This study reveals that rectal mucosa contains many innate immune factors important for host immunity to HIV and can limit viral replication in vitro. This indicates an important role for this fluid as the first line of defense against HIV.


Subject(s)
Immunologic Factors/genetics , Intestinal Mucosa/immunology , Intestinal Secretions/chemistry , Mouth Mucosa/immunology , Rectum/immunology , Saliva/chemistry , Antimicrobial Cationic Peptides/genetics , Antimicrobial Cationic Peptides/immunology , Cell Line , Cystatins/genetics , Cystatins/immunology , Epithelial Cells/cytology , Epithelial Cells/drug effects , Epithelial Cells/virology , Gene Expression , Gene Expression Profiling , HIV-1/drug effects , HIV-1/growth & development , Humans , Immunoglobulins/genetics , Immunoglobulins/metabolism , Immunologic Factors/pharmacology , Intestinal Secretions/immunology , Male , Proteomics , Saliva/immunology , Secretory Leukocyte Peptidase Inhibitor/genetics , Secretory Leukocyte Peptidase Inhibitor/immunology , Serpins/genetics , Serpins/immunology , Solubility , Cathelicidins
19.
J Microbiol Methods ; 101: 49-55, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24726869

ABSTRACT

Pseudomonas aeruginosa establishes chronic infections by forming biofilms; however studies of the virulence have focused on the planktonic form. Few in vitro co-culture models exist to study biofilm infections. We present a novel in vitro co-culture method examining the interactions between mature P. aeruginosa biofilms and human lung epithelial cells.


Subject(s)
Biofilms/growth & development , Coculture Techniques/methods , Plankton/physiology , Respiratory Mucosa/cytology , Respiratory Mucosa/microbiology , Apoptosis , Bacterial Adhesion , Humans , Interleukin-8 , Models, Biological
20.
AIDS Rev ; 16(1): 43-51, 2014.
Article in English | MEDLINE | ID: mdl-24522779

ABSTRACT

Interferons, induced early during viral infections, represent important regulators of both innate and adaptive immune responses, and provide protective effects against a wide range of pathogens, including HIV. Several in vitro studies and some in vivo data from HIV-exposed seronegative cohorts indicate that interferons and interferon-mediated immune responses are crucial in preventing early HIV replication. Following establishment of HIV infection, the uncontrolled (aberrant) activation of the immune system, in part regulated by interferon levels, contributes to HIV-1-induced immune activation and disease progression. Modulation of interferon responses prior to and during HIV infection shows promise for development of novel therapeutics to prevent HIV transmission, clear HIV infection, and dampen chronic immune activation. In this review we discuss the role that interferons play in protection from HIV infection, acute infection, and their role in HIV pathogenesis and disease progression. Lastly, we review recent advances in modulating interferon responses for purposes of developing novel HIV therapeutic approaches.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Interferons/therapeutic use , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...